First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and ...

Eli Lilly 3rd-generation GLP-1 retatrutide lowers A1C by 1.9% and reduces body weight by 33.3 pounds in phase 3 trial.

Retatrutide, a possible advance on GLP-1 drugs like Zepbound, significantly cut blood sugar and body weight in the study, a sign it might be similarly impactful against obesity.

Retatrutide, an experimental diabetes drug produced by Eli Lilly, helped some trial participants lose over 15% of their body ...

With the obesity numbers for Eli Lilly’s retatrutide already stacking up nicely, the company has rounded out its pitch for the triple agonist with top-line data on its ability to lower blood sugar ...

I love a good list. I have lists of house projects and plans. (Most of them will never come to fruition, but it's good to have HGTV dreams, I guess.) I have lists of article ideas, vacation spots, and ...

Mt Baker Medical is excited to unveil its newly developed physician-supervised GLP-1 weight loss initiative, aimed at delivering safe and effective solutions for medical weight management. This ...

GLP-1 drugs have ushered in a new era in weight loss. In just a few years, medications such as semaglutide and tirzepatide, known by the brand names Ozempic, Wegovy, Mounjaro and Zepbound, have gone ...

Americans want to lose weight but continuously fall short. As I've chronicled in this column year after year, weight-loss and related goals like exercising more and eating better are among the top New ...

Intermittent fasting has become one of the most talked-about weight loss trends in recent years, promising dramatic results with simple changes to when you eat. But a major Cochrane review suggests ...

Some patients in a clinical trial of one new drug lost so much weight that they became concerned and dropped out. By Dani Blum Scientists raced to make drugs that help people lose as much weight as ...

Evelyn Parr received funding from the Australian government's Medical Research Future Fund and the Diabetes Australia Research Program for work on time-restricted eating. Intermittent fasting has ...